ABT (Abbott Laboratories) Stock Financials & Earnings

Company Info & Key Metrics

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Dia...

CEORobert Ford

Country🇺🇸 United States

ExchangeNYSE

IPOMar 17, 1980

www.abbott.com

Revenue$11.5B

YoY Growth+4.4%

QoQ Growth+0.8%

Net Income$1.8B

EPS$1.02

Free Cash Flow$2.6B

Gross Margin57.0%

Op. Margin19.6%

Net Margin15.5%

FCF Margin22.9%

Rev Multiple (TTM)4.3x

P/E Ratio (TTM)29.4x

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$9.7B	$4.8B	$1.4B
Q2 23	$10.0B	$4.9B	$1.5B
Q3 23	$10.1B	$5.0B	$1.7B
Q4 23	$10.2B	$5.3B	$1.9B
Q1 24	$10.0B	$5.0B	$1.4B
Q2 24	$10.4B	$5.3B	$1.7B
Q3 24	$10.6B	$5.4B	$1.8B
Q4 24	$11.0B	$5.6B	$2.0B
Q1 25	$10.4B	$5.4B	$1.7B
Q2 25	$11.1B	$6.3B	$2.1B
Q3 25	$11.4B	$6.3B	$2.1B
Q4 25	$11.5B	$6.5B	$2.3B

Revenue Breakdown

Valuation

Quarter	P/S	P/E
Q1 23	4.6x	33.1x
Q2 23	4.8x	37.2x
Q3 23	4.8x	37.2x
Q4 23	4.8x	33.6x
Q1 24	4.8x	34.1x
Q2 24	4.7x	34.6x
Q3 24	4.7x	33.3x
Q4 24	4.6x	14.3x
Q1 25	4.5x	14.2x
Q2 25	4.5x	13.7x
Q3 25	4.4x	13.7x
Q4 25	4.3x	29.4x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	$1.1B	$763M
Q2 23	$1.2B	$696M
Q3 23	$1.9B	$1.3B
Q4 23	$3.0B	$2.3B
Q1 24	$1.0B	$627M
Q2 24	$2.0B	$1.4B
Q3 24	$2.7B	$2.1B
Q4 24	$2.9B	$2.1B
Q1 25	$1.4B	$933M
Q2 25	$2.0B	$1.5B
Q3 25	$2.8B	$2.3B
Q4 25	$3.3B	$2.6B

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$380M
Q2 23	$507M
Q3 23	$560M
Q4 23	$755M
Q1 24	$398M
Q2 24	$533M
Q3 24	$556M
Q4 24	$720M
Q1 25	$484M
Q2 25	$502M
Q3 25	$496M
Q4 25	$689M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-18.1%	-7.4%
Q2 23	-11.4%	-5.1%
Q3 23	-2.6%	-2.8%
Q4 23	+1.5%	-3.2%
Q1 24	+2.2%	+2.8%
Q2 24	+4.0%	+2.6%
Q3 24	+4.9%	+4.2%
Q4 24	+7.2%	+7.2%
Q1 25	+4.0%	+1.1%
Q2 25	+7.4%	+4.6%
Q3 25	+6.9%	+5.6%
Q4 25	+4.4%	+2.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$281M	2.9%
Q2 23	$132M	1.3%
Q3 23	$117M	1.2%
Q4 23	$114M	1.1%
Q1 24	$304M	3.1%
Q2 24	$141M	1.4%
Q3 24	$117M	1.1%
Q4 24	$111M	1.0%
Q1 25	$289M	2.8%
Q2 25	$142M	1.3%
Q3 25	$120M	1.1%
Q4 25	$113M	1.0%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$654M	—	$2.8B
Q2 23	$710M	—	$2.7B
Q3 23	$661M	—	$2.7B
Q4 23	$690M	—	$2.7B
Q1 24	$683M	—	$3.0B
Q2 24	$697M	—	$2.9B
Q3 24	$713M	—	$2.9B
Q4 24	$728M	—	$2.9B
Q1 25	$703M	—	$3.1B
Q2 25	$732M	—	$3.1B
Q3 25	$785M	—	$3.1B
Q4 25	$735M	$3.1B	—

Revenue Segments

Quarter	Diagnostic Products	Established Pharmaceutical Products	Medical Devices	Nutritional Products
Q1 23	$2.7B	$1.2B	$3.9B	$2.0B
Q2 23	$2.1B	$1.3B	$4.3B	$2.1B
Q3 23	$2.4B	$1.4B	$4.2B	$2.1B
Q4 23	$2.8B	$1.2B	$4.4B	$2.0B
Q1 24	$2.2B	$1.2B	$4.5B	$2.1B
Q2 24	$2.2B	$1.3B	$4.7B	$2.1B
Q3 24	$2.4B	$1.4B	$4.7B	$2.1B
Q4 24	$2.5B	$1.3B	$5.1B	$2.1B
Q1 25	$2.1B	$1.3B	$4.9B	$2.1B

Revenue by Geography

Quarter	Non-US	United States
Q1 23	$5.8B	$3.9B
Q2 23	$6.2B	$3.8B
Q3 23	$6.3B	$3.8B
Q4 23	$6.3B	$3.9B
Q1 24	$6.1B	$3.8B
Q2 24	$6.4B	$3.9B
Q3 24	$6.4B	$4.2B
Q4 24	$6.6B	$4.3B
Q1 25	$6.2B	$4.2B
Q2 25	$6.9B	$4.3B
Q3 25	$7.1B	$4.3B

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$9.2B	$371M	$9.5B
Q2 23	$7.8B	$320M	$8.2B
Q3 23	$6.7B	$338M	$7.0B
Q4 23	$6.9B	$383M	$7.3B
Q1 24	$6.3B	$367M	$6.7B
Q2 24	$7.0B	$232M	$7.2B
Q3 24	$7.6B	$230M	$7.8B
Q4 24	$7.6B	$351M	$8.0B
Q1 25	$6.5B	$312M	$6.8B
Q2 25	$7.0B	$331M	$7.3B
Q3 25	$7.5B	$222M	$7.7B
Q4 25	$8.5B	$417M	$8.9B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	1.75B	-0.1%
Q2 23	1.75B	-0.1%
Q3 23	1.75B	-0.1%
Q4 23	1.75B	-0.0%
Q1 24	1.75B	+0.1%
Q2 24	1.75B	+0.1%
Q3 24	1.75B	-0.2%
Q4 24	1.75B	-0.1%
Q1 25	1.75B	+0.1%
Q2 25	1.75B	+0.2%
Q3 25	1.75B	-0.1%
Q4 25	1.75B	-0.1%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$263K	77K
FY 15	$276K	74K
FY 16	$278K	75K
FY 17	$277K	99K
FY 18	$297K	103K
FY 19	$298K	107K
FY 20	$318K	109K
FY 21	$381K	113K
FY 22	$380K	115K
FY 23	$352K	114K
FY 24	$368K	114K
FY 25	$385K	115K